Author(s)

Hamza Abbas¹, Alia M. Attia¹, Ahmed A. S. Salem², Gamal Amira³, Adel Gabr⁴, Reham El Morshedy⁵, Mohamed Hamdy⁶

¹Radiotherapy Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
²Surgical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
³Surgical Oncology Department, National Cancer Institute, Cairo University, Giza, Egypt.
⁴Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
⁵Chest Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
⁶Radiodiagnosis Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.

Purpose: Our prospective phase II trial aims to show the feasibility of adjuvant paclitaxel-based concurrent chemoradiotherapy (CCRT) following doxorubicin and cyclophosphamide (AC) to get the survival benefit of taxanes addition and avoid delay of radiotherapy. Patients and Methods: A total of 63 patients with pT1-2, and pN1-3, M0 breast cancer underwent conservative surgery followed by adjuvant 4 cycles AC followed by 4 cycles Paclitaxel 175 mg/m² every 3 weeks. Adjuvant radiotherapy started during the first and second cycle of paclitaxel (CCRT). Toxicities evaluated at the base time, weekly during radiation therapy and every 3 months for 24 months for skin, pulmonary, cardiac, lymphedema, subcutaneous fibrosis and cosmoses. Survival reported at 2-year median follow-up. Results: At median follow up time of 24 months (6 - 30), we did not report any toxicity postpone or stop treatment and only two patients had grade III acute dermatitis. Fifty-two patients (82.5%) had satisfactory cosmoses and none of the patients developed local recurrence. Conclusion: Three-weekly paclitaxel during radiotherapy is considered safe without significant complications and acceptable cosmoses with excellent local control and could be considered to avoid radiotherapy delay.

Breast Cancer, BCS, Concurrent Radiotherapy and Paclitaxel

Abbas, H. , Attia, A. , Salem, A. , Amira, G. , Gabr, A. , El Morshedy, R. and Hamdy, M. (2017) Feasibility of Concurrent Radiotherapy and Paclitaxel-Based Chemotherapy after Conservative Surgery for Breast Cancer. Journal of Cancer Therapy, 8, 1068-1078. doi: 10.4236/jct.2017.811091.